Amicus Therapeutics, Inc(FOLD)
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
- 52-Week Range
- $5.92 – $14.50
- YTD
- +1.54%
- IV Rank (30D)
- 13.31
- Straddle Price
- $0.53
- P/C Vol Ratio
- 1.03
- Market Cap
- $4.5B
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834)
- Exchange
- XNAS
- Market Cap
- $4.5B
Amicus Therapeutics Inc is a biotechnology company focused to develop and deliver transformative medicines for people living with rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
Momentum Oscillators
Volume & Volatility
Data Summary
Choose Frenzy-Fast™ for quick analysis or Frenzy-Pro™ for comprehensive analysis.
Analysis includes technical indicators, news sentiment, risk assessment, and specific price levels to watch.
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2024-08-08 | After-Close | 13.47% | 1.41% | 0.10x | Within |
| 2024-11-06 | After-Close | 6.36% | 3.68% | 0.58x | Within |
| 2025-01-13 | After-Close | 3.79% | 0.22% | 0.06x | Within |
| 2025-05-01 | Pre-Market | 14.64% | 12.75% | 0.87x | Within |
| 2025-07-31 | After-Close | 14.19% | 5.51% | 0.39x | Within |
| 2025-11-04 | Pre-Market | 11.94% | 0.11% | 0.01x | Within |
| 2026-02-20 | After-Close | 54.37% | 0.00% | 0.00x | Within |
- IV Rank (30D)
- 13.31
- IV Rank (7D)
- 13.31
- Avg IV
- 99.5%
- Straddle (30D)
- $0.53
- Straddle (7D)
- $0.53
- P/C Volume
- 1.03
Each spread is ranked by a composite score built in three stages. Full documentation →
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Enter a ticker to render the implied volatility surface.
Enter a ticker to render the implied volatility smile.
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | SUSQUEHANNA INTERNATIONAL GROUP, LLP Custodian | $5.55M | 58.77% | 2026-03-31 |
| 2 | CITIGROUP INC Custodian | $1.45M | 15.33% | 2026-03-31 |
| 3 | CITADEL ADVISORS LLC Custodian | $614.55K | 6.51% | 2026-03-31 |
| 4 | TUDOR INVESTMENT CORP ET AL | $542.25K | 5.75% | 2026-03-31 |
| 5 | Walleye Trading LLC | $516.22K | 5.47% | 2026-03-31 |
| 6 | JANE STREET GROUP, LLC Custodian | $229.91K | 2.44% | 2026-03-31 |
| 7 | WOLVERINE TRADING, LLC Custodian | $227.08K | 2.41% | 2025-09-30 |
| 8 | GROUP ONE TRADING LLC Custodian | $224.13K | 2.38% | 2026-03-31 |
| 9 | SIMPLEX TRADING, LLC Custodian | $89.65K | 0.95% | 2026-03-31 |
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | SUSQUEHANNA INTERNATIONAL GROUP, LLP Custodian | $1.94M | 28.03% | 2026-03-31 |
| 2 | Walleye Trading LLC | $1.69M | 24.37% | 2026-03-31 |
| 3 | CITIGROUP INC Custodian | $1.45M | 20.90% | 2026-03-31 |
| 4 | JANE STREET GROUP, LLC Custodian | $1.05M | 15.17% | 2026-03-31 |
| 5 | GROUP ONE TRADING LLC Custodian | $352.82K | 5.10% | 2026-03-31 |
| 6 | SIMPLEX TRADING, LLC Custodian | $281.97K | 4.08% | 2026-03-31 |
| 7 | WOLVERINE TRADING, LLC Custodian | $162.77K | 2.35% | 2025-09-30 |
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-04-27 | Simon N.R. Harford | Chief Financial Officer | Disp (D) | −143,595 | $14.50 | -$2.08M | EDGAR |
| 2026-04-27 | GLENN SBLENDORIO | Director | Disp (D) | −142,564 | $14.50 | -$2.07M | EDGAR |
| 2026-04-27 | Samantha Prout | Chief Accounting Officer | Disp (D) | −125,951 | $14.50 | -$1.83M | EDGAR |
| 2026-04-27 | MICHAEL RAAB | Director | Disp (D) | −115,857 | $14.50 | -$1.68M | EDGAR |
| 2026-04-27 | Ellen Rosenberg | Chief Legal Officer | Disp (D) | −478,898 | $14.50 | -$6.94M | EDGAR |
| 2026-04-27 | Jeff Castelli | Chief Development Officer | Disp (D) | −427,089 | $14.50 | -$6.19M | EDGAR |
| 2026-04-27 | EIRY ROBERTS | Director | Disp (D) | −76,275 | $14.50 | -$1.11M | EDGAR |
| 2026-04-27 | BURKE W WHITMAN | Director | Disp (D) | −118,598 | $14.50 | -$1.72M | EDGAR |
| 2026-04-27 | David Michael Clark | Chief People Officer | Disp (D) | −221,811 | $14.50 | -$3.22M | EDGAR |
| 2026-04-27 | Lynn Dorsey Bleil | Director | Disp (D) | −113,941 | $14.50 | -$1.65M | EDGAR |
| 2026-04-27 | Bradley L Campbell | President and CEO | Disp (D) | −1,008,680 | $14.50 | -$14.63M | EDGAR |
| 2026-04-27 | MARGARET G MCGLYNN | Director | Disp (D) | −94,631 | $14.50 | -$1.37M | EDGAR |
| 2026-04-27 | CRAIG A WHEELER | Director | Disp (D) | −84,631 | $14.50 | -$1.23M | EDGAR |
| 2026-04-27 | Michael Aaron Kelly | Director | Disp (D) | −72,468 | $14.50 | -$1.05M | EDGAR |
| 2026-03-04 | Bradley L Campbell | President and CEO | Sell (S) | −22,500 | $14.35 | -$322.8K | EDGAR |
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | PERCEPTIVE ADVISORS LLC | 10%+ Owner | 20,724,424 | $300.30M | $0 | 1 | 2019-02-19 |
| 2 | JOSEPH EDELMAN | 10%+ Owner | 20,694,424 | $299.86M | $185.21M | 16 | 2018-10-05 |
| 3 | PERCEPTIVE LIFE SCIENCES MASTER FUND LTD | 10%+ Owner | 15,239,444 | $220.82M | $940.5K | 1 | 2015-10-08 |
| 4 | Jeremy Green | 10%+ Owner | 12,956,446 | $187.74M | $954.7K | 1 | 2016-06-13 |
| 5 | KRISHNA KITTU KOLLURI | 10%+ Owner | 4,584,311 | $66.43M | $36.91M | 1 | 2012-03-09 |
| 6 | M JAMES BARRETT | Director | 4,584,311 | $66.43M | $5.27M | 5 | 2013-06-17 |
| 7 | CHL Medical Partners II Side Fund, L.P. | 10%+ Owner | 4,084,011 | $59.18M | $0 | 1 | 2007-06-07 |
| 8 | CHL Medical Partners II, L.P. | 10%+ Owner | 4,084,010 | $59.18M | $0 | 1 | 2007-06-07 |
| 9 | Garden State Life Sciences Venture Fund L P | 10%+ Owner | 2,484,584 | $36.00M | $0 | 1 | 2007-06-07 |
| 10 | QUAKER BIO VENTURES LP | 10%+ Owner | 2,484,584 | $36.00M | $0 | 1 | 2007-06-07 |
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. Amendments (Form 144/A) and post-cancellation refilings can inflate this if you sum naively; the rollup above excludes filings with zero stated value.
Source & freshness: Parsed directly from EDGAR primary-doc XML. Daily refresh; new filings typically appear here the morning after they hit EDGAR.
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-03-02 | BRADLEY CAMPBELL | Director, Officer | 22,500 | $323.3K | 2026-03-02 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-01-20 | BRADLEY CAMPBELL | Director, Officer | 75,000 | $1.07M | 2026-01-20 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2025-12-19 | DAVID CLARK | Officer | 25,642 | $279.2K | 2025-12-19 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2025-12-15 | BRADLEY CAMPBELL | Director, Officer | 77,926 | $822.1K | 2025-12-15 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2025-12-15 | DAVID CLARK | Officer | 25,643 | $270.5K | 2025-12-15 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2025-12-01 | BRADLEY CAMPBELL | Director, Officer | 14,587 | $144.8K | 2025-12-01 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2025-11-26 | ELLEN ROSENBERG | Officer | 23,621 | $233.1K | 2025-11-26 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2025-11-25 | ELLEN ROSENBERG | Officer | 36,000 | $356.0K | 2025-11-25 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2025-11-24 | JEFFREY CASTELLI | Officer | 76,158 | $728.1K | 2025-11-24 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2025-11-24 | DAVID CLARK | Officer | 25,643 | $245.1K | 2025-11-24 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
| P/B Ratio | 16.6 |
| P/S Ratio | 7.2 |
| EV/EBITDA | 112.7 |
| TTM Revenue | $0.6B |
| TTM Net Income | $-0.0B |
| TTM EPS | $-0.09 |
| ROE | -9.9% |
| Debt/Equity | 1.43 |